Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.66 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | IL1B | P01584 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549346 | 1.00 | CRBN (0.66) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL22531990 | 0.88 | DDB1 (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29388131 | 0.88 | DDB1 (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL22845547 | 0.88 | CRBN (0.63) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL22532036 | 0.87 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29549308 | 0.87 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL21814681 | 0.86 | CRBN (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29658960 | 0.86 | CRBN (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL27385021 | 0.85 | CRBN (0.60) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24489953 | 0.85 | CRBN (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3813834-B1 | NEW CRBN MODULATORS | DANA FARBER CANCER INST INC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12030892-B2 | CRBN modulators | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220177466-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3953337-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | Dana-Farber Cancer Institute, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3952863-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | Dana-Farber Cancer Institute, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210277018-A1 | NEW CRBN MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210277018-A1 | NEW CRBN MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3813834-A1 | NEW CRBN MODULATORS | Dana Farber Cancer Institute, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2020263935-A1 | HCK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020210451-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210229-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | CRBN 360/4885DDB1 2437/4885IKZF3 4/4885 |
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | FGFR2, FGF2, FGFR1 | CRBN 801/4885DDB1 2520/4885IKZF3 700/4885 |
| US-20220177466-A1 | DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1) | KEAP1, NFE2L2, GSTK1 | CRBN 250/4885DDB1 106/4885IKZF3 595/4885 |
| US-12030892-B2 | CRBN modulators | CRBN, CRKL, CDR2 | CRBN 1/4885DDB1 626/4885IKZF3 1255/4885 |
| US-20210277018-A1 | NEW CRBN MODULATORS | CRBN, CRKL, CDR2 | CRBN 1/4885DDB1 560/4885IKZF3 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.